Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Use of the VisuMax™ Femtosecond Laser

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT01638390
Recruitment Status : Completed
First Posted : July 11, 2012
Results First Posted : March 21, 2019
Last Update Posted : March 21, 2019
Sponsor:
Information provided by (Responsible Party):
Carl Zeiss Meditec, Inc.

Brief Summary:
The objective of this clinical trial is to evaluate the safety and effectiveness of the Carl Zeiss Meditec VisuMax™ Femtosecond Laser lenticule removal procedure for the reduction or elimination of myopia from ≥ -1.00 D to ≤ -8.00 D with ≤ -0.50 D cylinder and MRSE (Manifest Refractive Spherical Equivalent) ≤ -8.25 D.

Condition or disease Intervention/treatment Phase
Myopia Device: Treatment with the VisuMax™ Femtosecond Laser Phase 1

Detailed Description:

This is a prospective multi-center clinical trial in which a total of 360 eyes of consecutive subjects will be enrolled, treated with the VisuMax™ Femtosecond Laser, and followed for a 12-month period. The study will be conducted at up to 8 clinical sites.

Enrollment will be phased such that 100 eyes will be initially enrolled and followed. When 50 of the initial eyes have reached the 3-month follow-up exam, an interim clinical study report will be submitted to FDA along with a request to continue enrollment up to 360 eyes.

Subjects will be screened for eligibility, and informed consent will be obtained from those who meet screening criteria and are interested in participating in the study. Eligible subjects will be examined preoperatively to obtain a medical history and to establish a baseline ocular condition. Baseline and postoperative measurements will include manifest refraction, cycloplegic refraction, distance visual acuity (best corrected and uncorrected), slit-lamp examination, fundus examination, corneal topography, central corneal pachymetry, mesopic pupil measurement, wavefront analysis, mesopic contrast sensitivity, and intraocular pressure (IOP).

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 357 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Use of the VisuMax™ Femtosecond Laser Lenticule Removal Procedure for the Correction of Myopia
Study Start Date : July 2012
Actual Primary Completion Date : April 2016
Actual Study Completion Date : April 2016

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Treatment of Myopia
The reduction or elimination of myopia from ≥ -1.00 D to ≤ -8.00 D with ≤ -0.50 D cylinder and MRSE ≤ -8.25 D.
Device: Treatment with the VisuMax™ Femtosecond Laser
The reduction or elimination of myopia from ≥ -1.00 D to ≤ -8.00 D with ≤ -0.50 D cylinder and MRSE ≤ -8.25 D.
Other Name: VisuMaxTM Femtosecond Laser




Primary Outcome Measures :
  1. Effectiveness- Predictability [ Time Frame: 12 months ]
    Number of participants with a decrease in manifest refraction spherical equivalent (MRSE) to within ± 1.00 D and ± 0.50 D of the intended refractive outcome at the point at which stability is first reached. The MRSE is the amount of prescription needed to obtain your best corrected vision as compared to your preoperative best corrected vision. A minimum of 75% of eyes should have an achieved refraction within ± 1.00 D of the intended outcome, and at least 50% of eyes should be within ± 0.50 D of the intended outcome.

  2. Effectiveness- Improvement in UCVA Following Treatment [ Time Frame: 12 month ]
    Number of participants with uncorrected visual acuity (UCVA) of 20/40 or better at the point of stability. .This is vision without any form of prescription. A target of 85% of participants is required.

  3. Stability Criteria- Change Between Visits Within 1.00 Diopter (D) [ Time Frame: 6 months ]
    Number of participants with a change in postoperative refraction within 1.00 D between the 3 and 6 month visits. Stability was identified at the 6 month visit for the study.

  4. Safety- Preservation of Best-Spectacle Corrected Visual Acuity (BSCVA) [ Time Frame: 12 months ]
    1. Number of participants with worse than 20/40 visual acuity with a preoperative BSCVA (Best Spectacle Corrected Visual Acuity) 20/20 or better. Target is less than 1% of study participants.
    2. Less than 5% of participants with BCVA loss ≥ 2 lines

  5. Safety- Induced Manifest Refractive Astigmatism [ Time Frame: 12 months ]
    Number of participants with an increase of astigmatism of greater than 2.00 D cylinder from the preoperative values. Target is less than 5% of participants.

  6. Safety- Adverse Events [ Time Frame: 12 months ]
    Number of participants for each type of adverse event. Target of less than 1% of participants for each type of adverse event.

  7. Safety- Contrast Sensitivity [ Time Frame: 12 months ]
    Number of participants who increased, remained the same, and decreased in contrast sensitivity. There are 4 different frequencies (1.5, 3.0, 6.0, and 12.0) which will be tested and are more difficult to detect as the frequency number increases.

  8. Stability Criteria- Change Between Visits Within 0.50 Diopter (D) [ Time Frame: 6 months ]
    Number of participants with a change in postoperative refraction within 0.50 D between the 3 and 6 month visits. Stability was identified at the 6 month visit for the study.


Secondary Outcome Measures :
  1. Safety- Patient Symptoms [ Time Frame: 12 months ]
    A standardized quality of vision (QoV) questionnaire was used in the study. A score is generated and was used to compare the results from baseline to the 12 month visit. Number of participants who improved, stayed the same, or worsened with regards to the frequency, severity, and bothersomeness of symptoms are reported.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   22 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Male and female subjects age 22 years of age and older;
  • Spherical myopia from ≥ -1.00 D to ≤ -8.00 D, with ≤ -0.50 D cylinder and MRSE ≤ -8.25 D in the eye to be treated;
  • A stable refraction for the past year, as demonstrated by a change in MRSE of ≤ 0.50 D in the eye to be treated;
  • A difference between cycloplegic and manifest refractions of < 0.75 D spherical equivalent in the eye to be treated;
  • UCVA worse than 20/40 in the eye to be treated;
  • BSCVA at least 20/20 in the eye to be treated;
  • Discontinue use of contact lenses for at least 2 weeks (for hard lenses) or 3 days (for soft lenses) prior to the preoperative examination, and through the day of surgery;
  • All contact lens wearers must demonstrate a stable refraction (within ±0.5 D), as determined by MRSE, on two consecutive examinations at least 1 week apart, in the eye to be treated;
  • Central corneal thickness of at least 500 microns in the eye to be treated;
  • Willing and able to return for scheduled follow-up examinations;
  • Able to provide written informed consent and follow study instructions in English.

Exclusion Criteria:

  • Mesopic pupil diameter > 8.0 mm;
  • Cylinder > -0.50 D;
  • Treatment depth is less than 250 microns from the corneal endothelium;
  • Eye to be treated is targeted for monovision;
  • Fellow eye has BSCVA worse than 20/40;
  • Abnormal corneal topographic findings, e.g. keratoconus, pellucid marginal degeneration in either eye;
  • History of or current anterior segment pathology, including cataracts in the eye to be treated;
  • Clinically significant dry eye syndrome unresolved by treatment in either eye;
  • Residual, recurrent, active ocular or uncontrolled eyelid disease, corneal scars or other corneal abnormality such as recurrent corneal erosion or severe basement membrane disease in the eye to be treated;
  • Ophthalmoscopic signs of progressive or unstable myopia or keratoconus (or keratoconus suspect) in either eye;
  • Irregular or unstable (distorted/not clear) corneal mires on central keratometry images in either eye;
  • History of ocular herpes zoster or herpes simplex keratitis;
  • Deep orbits, strong blink, anxiety, pterygium, or any other finding suggesting difficulty in achieving or maintaining suction;
  • Difficulty following directions or unable to fixate;
  • Previous intraocular or corneal surgery of any kind in the eye to be treated, including any type of surgery for either refractive or therapeutic purposes;
  • History of steroid-responsive rise in intraocular pressure, glaucoma, or preoperative IOP > 21 mmHg in either eye;
  • History of diabetes, diagnosed autoimmune disease, connective tissue disease or clinically significant atopic syndrome;
  • Immunocompromised or requires chronic systemic corticosteroids or other immunosuppressive therapy that may affect wound healing;
  • History of known sensitivity to planned study medications;
  • Participating in any other ophthalmic drug or device clinical trial during the time of this clinical investigation;
  • Pregnant, lactating, or of child-bearing potential and not practicing a medically approved method of birth control.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01638390


Locations
Layout table for location information
United States, Colorado
Dishler Laser Institute
Greenwood Village, Colorado, United States, 80111
United States, Florida
Bascom Palmer Eye Institute
Miami, Florida, United States, 33136
United States, Kansas
Discover Vision Centers
Leawood, Kansas, United States, 66211
United States, South Dakota
Vance Thompson Vision
Sioux Falls, South Dakota, United States, 57108
United States, Wisconsin
Davis Duehr Dean
Madison, Wisconsin, United States, 53717
Sponsors and Collaborators
Carl Zeiss Meditec, Inc.
Investigators
Layout table for investigator information
Principal Investigator: Jon Dishler, M.D. Dishler Laser Institute
Principal Investigator: John Doane, M.D. Discover Vision Centers
Principal Investigator: Vance Thompson, M.D. Vance Thompson Vision Clinic, Prof., LLC
Principal Investigator: William Culbertson, M.D. Bascom Palmer Eye Institute
Principal Investigator: Sonia Yoo, M.D. Bascom Palmer Eye Institute
Principal Investigator: John Vukich, M.D. Davis Duehr Dean
Layout table for additonal information
Responsible Party: Carl Zeiss Meditec, Inc.
ClinicalTrials.gov Identifier: NCT01638390    
Other Study ID Numbers: VISUMAX-2012-1
First Posted: July 11, 2012    Key Record Dates
Results First Posted: March 21, 2019
Last Update Posted: March 21, 2019
Last Verified: December 2018
Additional relevant MeSH terms:
Layout table for MeSH terms
Myopia
Refractive Errors
Eye Diseases